ELMO3: A Potential Drug Target and Biomarker (G79767)

Target Name: ELMO3

NCBI ID: G79767

ELMO3

ELMO3: A Potential Drug Target and Biomarker

ELMO3, a protein expressed in the human brain, has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders. ELMO3 is a scaffold protein that plays a critical role in the structure and function of the brain microtubules, which are responsible for the transport of various cellular and molecular components within the brain. The deregulation of microtubules has been implicated in the development of numerous neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. Therefore, targeting ELMO3 has the potential to provide new treatments for these disorders.

ELMO3 is a 21-kDa protein that is expressed in the brain and other tissues. It is composed of a unique transmembrane domain and a cytoplasmic tail that contains a unique GFP-like domain. The GFP-like domain is a characteristic of the ELMO3 protein and is involved in the formation of microtubules. It is known that the GFP-like domain interacts with the microtubule protein TP100, which is also a critical protein for the formation of microtubules. This interaction between ELMO3 and TP100 suggests that ELMO3 may play a role in the regulation of microtubule dynamics and stability.

Several studies have demonstrated that ELMO3 is involved in the regulation of microtubule dynamics and stability. For example, ELMO3 has been shown to interact with TP100 and prevent its phosphorylation. This interaction between ELMO3 and TP100 may play a role in the regulation of microtubule stability and dynamics. Additionally, ELMO3 has been shown to be involved in the regulation of the stability of the microtubule-associated protein (MAP) complex. MAP is a protein that is involved in the regulation of various cellular processes in the brain, including cell signaling and neurotransmission. The regulation of MAP complex stability by ELMO3 may be involved in the regulation of neurotransmission and brain function.

ELMO3 has also been shown to be involved in the regulation of the formation and stability of the neurotransmitter synapse. Neurons release neurotransmitters, such as dopamine and serotonin, at the synapse, which is the site of communication between the neuron and the target cell. The regulation of synapse formation and stability by ELMO3 may be involved in the regulation of neurotransmission and brain function.

In addition to its involvement in the regulation of microtubule dynamics and stability, ELMO3 has also been shown to be involved in the regulation of inflammation and cellular stress. Chronic inflammation and cellular stress have been implicated in the development of various neurological and psychiatric disorders, including Alzheimer's disease and depression. The regulation of inflammation and cellular stress by ELMO3 may be involved in the development and progression of these disorders.

The potential drug target for ELMO3 is the reduction of ELMO3 expression and the inhibition of ELMO3-mediated signaling pathways. This can be achieved through various therapeutic approaches, including inhibition of the activity of the TP100-ELMO3 interaction, inhibition of the formation of the MAP-ELMO3 interaction, or inhibition of the activity of ELMO3 in the regulation of synapse formation and stability. These therapeutic approaches may be effective in treating neurological and psychiatric disorders associated with ELMO3 dysfunction, including Alzheimer's disease, Parkinson's disease, and depression.

In conclusion, ELMO3 is a protein that is involved in the regulation of microtubule dynamics and stability, as well as the regulation of inflammation and cellular stress. The potential drug target for ELMO3 is the reduction of ELMO3 expression and the inhibition of ELMO3-mediated signaling pathways. These therapeutic approaches may be effective in treating neurological and psychiatric disorders associated with ELMO3 dysfunction, including Alzheimer's disease, Parkinson's disease, and depression. Further research is needed to fully understand the role of ELMO3 in the regulation of brain function and the development of neurological and psychiatric disorders.

Protein Name: Engulfment And Cell Motility 3

Functions: Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic cells and cell motility. Acts in association with DOCK1 and CRK. Was initially proposed to be required in complex with DOCK1 to activate Rac Rho small GTPases. May enhance the guanine nucleotide exchange factor (GEF) activity of DOCK1 (By similarity)

The "ELMO3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELMO3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets